{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.5","upperLimit":"16.2","value":"5.9"},{"groupId":"OG001","lowerLimit":"0.3","upperLimit":"90.0","value":"6.6"},{"groupId":"OG002","lowerLimit":"3.1","upperLimit":"32.4","value":"8.3"},{"groupId":"OG003","lowerLimit":"0.4","upperLimit":"71.5","value":"6.7"},{"groupId":"OG004","lowerLimit":"1.0","upperLimit":"8.8","value":"1.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"85"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"47"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"description":"Time from date of treatment start until date of death due to any cause or last Follow-up.","dispersionType":"Full Range","groups":[{"description":"Patients receive azacitidine IV over 1 hour or SC on days 1-7 or days 1-4 and 7-9. Patients also receive nivolumab IV over 60 minutes on days 1 and 14 (courses 1-4) or on day 1 (course 5 and all subsequent courses). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nNivolumab: Given IV","id":"OG000","title":"Arm 1 A Lead-In (Azacitidine, Nivolumab)"},{"description":"Patients receive azacitidine IV over 1 hour or SC on days 1-7 or days 1-4 and 7-9. Patients also receive nivolumab IV over 60 minutes on days 1 and 14 (courses 1-4) or on day 1 (course 5 and all subsequent courses). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nNivolumab: Given IV","id":"OG001","title":"Arm 1 B (Azacitidine, Nivolumab)"},{"description":"Patients receive azacitidine and nivolumab as Arm I. Patients also receive ipilimumab IV over 90 minutes on day 1 and then every 6 or 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nIpilimumab\n\nNivolumab: Given IV","id":"OG002","title":"Arm 2 A Lead-In (Azacitidine, Nivolumab, Ipilimumab)"},{"description":"Patients receive azacitidine and nivolumab as Arm I. Patients also receive ipilimumab IV over 90 minutes on day 1 and then every 6 or 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nIpilimumab\n\nNivolumab: Given IV","id":"OG003","title":"Arm 2 B (Azacitidine, Nivolumab, Ipilimumab)"},{"description":"Patients will receive therapy with nivolumab IV infusion on Day 8 and Day 22 (+/-3 days) of each 5-azacyidine cycle for first 4 cycles or until CR (whichever occurs earlier) followed by a maintenance regimen (one dose of nivolumab on Day 8 of each cycle of 5-azacytdine). Venetoclax will be administered orally daily on Days 1-21 of the first cycle; and Days 1-14 or Days 1-21 for subsequent cycles.\n\nAzacitidine: Given SC or IV\n\nVenetoclax: Given Orally\n\nNivolumab: Given IV","id":"OG004","title":"Arm 3 A Lead-In (Azacitidine, Nivolumab, Venetoclax)"}],"paramType":"MEDIAN","populationDescription":"There were Zero participants enrolled on Arm 3 B due to no responses in the lead in phase.","reportingStatus":"POSTED","timeFrame":"Up to 7 years, 6 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}